Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dawn Wilson

Obstetrics & Gynecology Yukon, OK Doctor of Osteopathy

NPI 1033209036 CMS profile 274013

436 S Mustang Rd, Yukon, OK 73099

Open in the dashboard

General payments

$36,064

301 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dawn Wilson of Yukon, OK is reported in the CMS Open Payments database as having received $36,064 across 301 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $114 7
2024 General $604 47
2023 General $695 57
2022 General $701 57
2021 General $3,361 41
2020 General $5,305 26
2019 General $25,284 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dawn Wilson
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Dawn Wilson were reported at $114. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Dawn Wilson Obstetrics & Gynecology median Middle half National median
2019 $25,284 $172 $62–$391 $163
2020 $5,305 $94 $36–$222 $114
2021 $3,361 $136 $42–$369 $132
2022 $701 $160 $50–$433 $149
2023 $695 $169 $56–$423 $160
2024 $604 $152 $50–$371 $164
2025 $114 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $34,296 184 payments
  2. Mayne Pharma Inc. $487 41 payments
  3. TherapeuticsMD, Inc. $183 12 payments
  4. Pfizer Inc. $135 8 payments
  5. Astellas Pharma US Inc $113 6 payments
  6. Antares Pharma, Inc. $109 6 payments
  7. Avion Pharmaceuticals $96 6 payments
  8. Currax Pharmaceuticals LLC $88 7 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $58 4 payments
  10. Revance Therapeutics, Inc. $48 2 payments
  11. Other $450 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,938 21 payments
  2. Food and Beverage $4,097 267 payments
  3. Travel and Lodging $1,029 13 payments
Products named General payments · program years 2019–2025
  1. Orilissa Endocrinology $25,085 53 payments
  2. ORIAHNN $5,353 28 payments
  3. ORILISSA Womens Health $3,172 26 payments
  4. QULIPTA $650 62 payments
  5. UBRELVY $274 30 payments
  6. NEXTSTELLIS $156 14 payments
  7. LO LOESTRIN FE $149 11 payments
  8. NURTEC ODT $135 8 payments
  9. CONTRAVE $91 7 payments
  10. ANNOVERA $78 5 payments
  11. Other $1,502 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

1,867

Median for Obstetrics & Gynecology: 65

Drug cost

$165,811

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

35.3%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 53 $55,379
Ozempic Semaglutide Brand 31 $35,645
Myrbetriq Mirabegron Brand 20 $17,595
Progesterone Progesterone, Micronized Brand 245 $13,434
Glyxambi Empagliflozin/Linagliptin Brand 12 $7,212
Testosterone Cypionate Generic 87 $4,872
Estradiol Generic 109 $4,289
Vyvanse Lisdexamfetamine Dimesylate Brand 11 $4,114
Liothyronine Sodium Generic 89 $3,541
Armour Thyroid Thyroid,pork Brand 56 $2,518

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$38,224

Of which drugs: $58

Medicare patients

179

Average age 69

Services billed

695

145 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 51%
Depression 26%
Diabetes 23%
Ischemic heart disease 20%
Chronic kidney disease 15%
COPD 11%
Osteoporosis 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 26 $12
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 52 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $252
$252 — —
UBRELVY
  • AbbVie, Inc. $61
$61 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $48
$48 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $25
$25 — —
XYOSTED
  • Antares Pharma, Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

301 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record